102 results
8-K
EX-2.1
HGENQ
Humanigen, Inc
8 Jan 24
Entry into a Material Definitive Agreement
5:02pm
and immuno-oncology monoclonal antibodies, lenzilumab, ifabotuzumab and HGEN005;
WHEREAS, Seller is developing lenzilumab in chronic myelomonocytic … leukemia, a rare blood cancer, for which the Precision Approach to Chronic Myelomonocytic Leukemia study is underway, and is continuing its plans
8-K
EX-99.1
HGENQ
Humanigen, Inc
14 Nov 22
Humanigen Reports Third Quarter 2022 Financial Results
4:16pm
the development of lenzilumab in chronic myelomonocytic leukemia (CMML), a rare blood cancer, for which the PREACH-M study is already underway … . Humanigen is developing lenzilumab as a treatment for chronic myelomonocytic leukemia and acute graft versus host disease. Humanigen is also exploring
8-K
EX-99.1
di7 de4oecyd1vc
12 Aug 22
Humanigen Reports Second Quarter 2022 Financial Results
4:07pm
8-K
EX-99.1
lk7f0p50fw4
26 Jul 22
Humanigen Implements Strategic Realignment of Pipeline and Resources to Achieve Key Clinical Milestones
4:05pm
8-K
EX-99.1
013jeb 7bh6wfd
5 May 22
Humanigen Reports First Quarter 2022 Financial Results
4:05pm
424B5
i8g70i78u6a
14 Apr 22
Prospectus supplement for primary offering
5:27pm
8-K
EX-99.1
srm7sp2icpfu4h
12 Apr 22
Regulation FD Disclosure
9:00am
8-K
EX-99.1
ygjcd6ecn2 iqakwba
28 Feb 22
Humanigen Reports Year-End 2021 Financial Results
4:01pm
8-K
EX-99.1
j3wsj7kwbvyqlo
2 Dec 21
Other Events
8:00am
8-K
EX-99.1
outxqnai7va1kps
12 Nov 21
Results of Operations and Financial Condition
4:01pm
8-K
EX-99.1
n6k4qn0
9 Nov 21
Regulation FD Disclosure
8:00am